Key Highlights
● Quarterly Revenue rose about 7%, with growth drugs expanding at a double-digit pace.
● Full-year revenue guidance moved higher while adjusted per-share guidance was lowered.
● Large acquired research charges weighed on reported and adjusted earnings.
● A cost program targets roughly $2 billion in annual savings by next year-end.
Bristol-Myers Squibb (NYSE:BMY) closed its latest Earnings season with a report that pulled in two directions at once. Revenue for the third quarter grew at a mid-single-digit to high-single-digit pace and came in above what the market had pencilled in, while adjusted Earnings Per Share also cleared expectations. Yet the drugmaker lowered the midpoint of its full-year adjusted per-share guidance even as it nudged its revenue guidance upward, a combination that told the story of a company paying heavily today for the medicines it hopes will carry it through the next decade.
The main driver of the split was a sharp rise in charges tied to acquired research projects. Instalment payments to BioNTech, an upfront payment under a licensing arrangement with China-based Hengrui, and the cost of a priority review voucher all ran through the earnings statement as expense rather than being capitalized, pressing down on reported and adjusted earnings. At the same time, long-running cancer franchises that once produced enormous sales continued to erode as generic competition arrived, so the growth drugs were running uphill against a steady decline in the old base.
The quarter was reported at the end of October and filed in full with the Securities and Exchange Commission shortly afterwards. It is a factual summary of public disclosures, not a view on where the stock should trade.
What exactly did Bristol-Myers Squibb report for the third quarter?
Total revenue for the quarter reached a little over $13 billion, roughly 7% higher than in the same period a year earlier. For the first nine months of the year, revenue was up about 5%. The filing breaks the Business into two buckets, a growth portfolio of newer and still-expanding medicines and a legacy portfolio of mature brands, and the contrast between them frames almost every other number in the report.
The growth portfolio produced more than $7.5 billion of sales in the quarter, an increase of about 12%. The legacy portfolio generated a little over $5 billion, basically flat against the prior-year quarter. That flat reading hides a lot of movement beneath it, because one very large product rose strongly while several older cancer drugs fell steeply, and the two largely cancelled out.
On the bottom line, net earnings attributable to the company were a little above $2 billion, which translated to a diluted per-share figure close to $1 on a reported basis. That was marginally lower than a year earlier. The adjusted per-share figure excluded some items but still came in below the prior-year quarter, even though it beat the level the market had expected going in.
Which medicines carried the growth portfolio this time?
Management said eight products now run at an annualized sales rate above $1 billion. Among the names that stood out were Reblozyl for anemia linked to blood disorders, Breyanzi, the cell therapy used against several lymphomas, and Camzyos, the heart medicine for obstructive hypertrophic cardiomyopathy. Each posted double-digit growth compared with the year-earlier quarter, and Camzyos also gained a pediatric indication during the period.
Opdivo Qvantig, the under-the-skin version of the company's flagship immuno-oncology drug, was another bright spot. Its sales were several times higher than a year earlier as the formulation was adopted at more treatment centers. The intravenous version of Opdivo slipped modestly, which is the pattern the company has been steering toward, since the subcutaneous product extends the franchise's life as the original version ages.
New launches also featured in the commentary. The company highlighted the arrival of a treatment for multiple myeloma and pointed to several registrational readouts and regulatory approvals during the period, with more expected. The diversity of these items matters because the growth portfolio is no longer dependent on a single cancer or cardiovascular name, a concentration that has worried some observers of the drug sector for years.
Why did the largest product rise so sharply while older brands fell?
Eliquis, the blood thinner developed with Pfizer, is the single biggest line item in the report and its quarterly sales were far higher than in the same quarter of the previous year. The comparison is flattered by timing effects in rebates and discounts, which can swing from quarter to quarter in the American market, so the jump should not be read as a pure measure of demand.
Company commentary also flagged that Eliquis will lose exclusivity in parts of Europe, and that headwind is expected to weigh on revenue as generic versions enter. The American Franchise remains protected for longer, but the combination of European erosion and ongoing pricing pressure explains why management keeps stressing the need for new products to take over from existing ones.
The other side of the ledger is clear in the filing. Revlimid and Pomalyst, two older myeloma medicines, each generated far less revenue than a year earlier as generic competition widened. Between them, they gave up well over half a billion dollars of quarterly sales compared with the prior-year period. That steady subtraction is the reason growth drugs must expand quickly just for total revenue to keep rising.
How did research charges reshape the earnings picture?
Accounting rules require that payments for early-stage rights to unproven compounds be expensed when incurred, and the company has been signing many such agreements. Charges for acquired in-process research were well over $1.5 billion in the quarter, more than double the level a year earlier. Those charges reduce adjusted earnings, which is why the per-share guidance moved down even as sales guidance moved up.
The filing describes three particular items. A licensing arrangement with Hengrui gave the company rights to a bundle of early-stage Assets for an upfront payment, with a further fixed payment due next year and a large pool of milestone and Royalty payments possible depending on success. A collaboration with BioNTech carries yearly anniversary installments that add up to billions through the end of the decade. And the company acquired a priority review voucher, recorded as research expense.
None of these outlays guarantees a medicine will reach the market. They do, however, reveal where management is putting capital, which is in a broad set of external bets at a time when internal discovery alone would not refill the pipeline fast enough. The cost shows up immediately, while any reward would arrive years later, if at all.
What changed in the full-year guidance for Bristol-Myers Squibb?
Management moved the midpoint of its full-year revenue guidance up by roughly 1%, to about $50 billion. That was an acknowledgment that sales are tracking a little stronger than expected, helped by the growth portfolio and the timing effects mentioned above. Raising the Top Line is a signal that Demand for the key medicines is staying firm as planned.
The adjusted per-share midpoint, however, was reduced by a little over 6%, to about $6.5. The company attributed this mostly to the acquired research charges and to the cost of launches and ongoing research spending. Operating Margin on an adjusted basis fell to the low twenties from the mid-twenties a year earlier, a decline management tied to higher research spending, launch costs and one-time contract termination costs.
The pairing of a higher revenue figure with a lower per-share figure is not unusual for a large drugmaker in the middle of a portfolio transition, but it is a reminder that headline revenue and earnings can move independently when deal expense is large. Readers following Value Stocks will recognize the pattern, since several mature pharmaceutical groups are currently trading near-term earnings for pipeline breadth.
What does the Cash Flow and Balance Sheet show?
Operating cash flow for the first nine months was lower than a year earlier, and the quarterly filing ties much of the gap to a large outflow for rebates and discounts. Cash and equivalents stood at a little under $10 billion at the end of September, along with several billion more in short-term marketable Debt securities, which gives the company a comfortable cushion for its near-term commitments.
Long-term debt edged lower, and Short-Term Debt dropped by more than half as the company repaid obligations during the year. Dividend payments for the nine months were slightly above those of the prior year and remain a steady cash outlay. The balance of the numbers shows a company that is funding deals and payouts from operations while still trimming borrowings at the margin.
The company also disposed of its majority stake in a Shanghai-based joint venture for cash proceeds and recorded a gain. Smaller portfolio moves like this one show management tidying non-core pieces while it commits larger sums to new research collaborations.
How is the cost program supposed to help?
A multi-year restructuring plan first launched in the previous few years is now well advanced. According to the quarterly filing, most of the planned charges have been incurred, and management expects the effort to deliver approximately $2 billion of annual savings by the end of next year. These savings are intended to leave room for continued research and launch spending without eroding margins indefinitely.
The chief financial officer, David Elkins, said the company remains focused on financial discipline while balancing spending on its growth drivers. In plain terms, the plan is to keep trimming general and administrative expense and Manufacturing complexity in order to support a heavier research budget. Whether the savings arrive fast enough to offset the legacy decline is the central operating question for the next several quarters.
Separately, the company announced American manufacturing commitments, including a large campus in Houston and added radiopharmaceutical capacity in Indiana. Such projects are long-lived and capital-intensive, and they align with the broader industry push to build Supply closer to the American market.
Which pipeline readouts are on the calendar?
Management pointed to a series of late-stage readouts ahead. Milvexian, the oral clotting-pathway inhibitor being developed with Johnson & Johnson, has studies in stroke prevention and atrial fibrillation, and these are widely viewed as the most consequential trials on the schedule because success would give the company a successor to Eliquis in an adjacent field.
Sotyktu, already approved for plaque psoriasis, is being tested in lupus, a condition with limited good options. Other programs include admilparant in idiopathic pulmonary fibrosis and a range of neuroscience and cancer studies. The company reported positive late-stage data for its newest myeloma medicine and interim findings in rare tumors during the period.
Pipeline news carries a different kind of weight from quarterly sales. A single positive or negative trial result can reshape how the market judges the next decade of revenue, so these readouts are likely to drive more attention than the next set of quarterly figures. The timing of each is subject to enrollment and regulatory schedules that the company does not control.
What legal and tax matters remain open?
The quarterly filing is explicit that some old matters are not yet resolved. The company is contesting transfer-pricing adjustments proposed by the Internal Revenue Service for a long-ago stretch of years and is pursuing the administrative appeals process. The filing states that the timing of final resolution is uncertain and that the outcome could have a material effect on the company.
Litigation and settlement charges in the quarter were tiny, a stark change from the prior-year quarter, which included a sizable charge tied to a securities case. The quarterly effective tax rate was also much lower than a year earlier, partly because the earlier period included added tax reserves. These swings are a reminder that GAAP results contain items that do not repeat evenly.
Pricing arrangements with the federal government are a further backdrop. The company earlier announced an agreement with the American government on access and affordability, and the timing of rebates and discounts continues to move reported figures from one quarter to the next. The details are in the filing for readers who want the full legal and commercial language.
Where does the stock sit in the wider market conversation for Bristol-Myers Squibb?
The shares of the company are a constituent of the Russell 1000, and the stock traded modestly higher after the report, according to market coverage. Its Market Value sits above $100 billion, making it one of the larger American pharmaceutical groups by size. The share reaction was mild, a sign that the guidance trade-off was largely understood.
Value-oriented screens often capture companies of this type because earnings are sizable relative to the share price while growth is moderate. That label describes a statistical profile, not a statement about price direction, and it can change quickly as pipeline results arrive or as legacy erosion proceeds faster than expected.
For readers tracking the pharmaceutical group, the most useful comparison is how each large company is bridging the gap between expiring products and new ones. The company's approach combines internal launches, external licensing and a cost program, an approach many peers are also following in their own ways.






Please wait processing your request...